Relationship between liver pathologic histology and levels of serum hepatitis B virus DNA in patients with HBeAg-positive and -negative chronic hepatitis B

Li, Shi-Zhou; Jiang, Yong-Fang

doi:10.11569/wcjd.v14.i33.3241

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBeAg is a marker of the hepatitis B virus, and when it disappears, it means the patient's immune system has begun to control the infection. Although antiviral therapy has become the standard treatment for chronic hepatitis B, some patients still cannot achieve HBeAg clearance [3][4][5][6][7] . This may be caused by a variety of factors, including but not limited to the following: (i) Insufficient duration of treatment: In some cases, antiviral treatment needs to be continued for several years or even longer to achieve HBeAg clearance.…”

Section: Discussionmentioning

confidence: 99%

Predictive Value of Serum pgRNA on HBeAg Clearance in Patients with Chronic Hepatitis B with Low HBeAg Levels Treated with Pegylated Interferon

Lyu

et al. 2023

JCNR

View full text Add to dashboard Cite

Objective: To study the predictive value of serum pregenomic RNA (pgRNA) on HBeAg clearance in patients with chronic hepatitis B with low HBeAg levels during pegylated interferon therapy. Methods: Twenty chronic hepatitis B patients with HBeAg positive and quantitative <50S/CO were selected for this study. The subjects underwent pegylated interferon therapy for 48–96 weeks and were followed up in the outpatient clinic after treatment. The patients were then divided into groups based on whether their HbeAg turned negative. The predictive ability of each indicator for HBeAg negative conversion was evaluated in the HBeAg negative group and the HBeAg positive group. Results: The results of logistic regression analysis suggested that pgRNA and HBcrAg were better indicators for predicting the clearance of HBeAg after treatment. Conclusion: For patients with chronic hepatitis B with low HBeAg levels, pgRNA is a good indicator in predicting HBeAg clearance during pegylated interferon therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictive Value of Serum pgRNA on HBeAg Clearance in Patients with Chronic Hepatitis B with Low HBeAg Levels Treated with Pegylated Interferon

Lyu

et al. 2023

JCNR

View full text Add to dashboard Cite

show abstract

“…HBV-pgRNA is an important component in the replication of HBV and plays a key role in HBV infection. Recent studies have shown that HBV-pgRNA detection has certain clinical value in evaluating the treatment response and efficacy in hepatitis B patients [8,9] . In the present study, we explore the clinical value of HBV-pgRNA detection in the treatment of hepatitis B and analyze its advantages and limitations in clinical application.…”

Section: Discussionmentioning

confidence: 99%

Clinical Value of Hepatitis B Virus RNA Detection in Patients with Chronic Hepatitis B Infection

Lyu

2023

PAR

View full text Add to dashboard Cite

Objective: To study the clinical value of hepatitis B virus pregenomic RNA (HBV-pgRNA) detection in the treatment of hepatitis B. Methods: 60 patients with hepatitis B were included in the study. Serum HBV-pgRNA and HBV DNA levels in different phases of infection and during treatment were detected, and serum hepatitis B surface antigen (HbsAg) titer was detected by chemiluminescent immunoassay. DNA was extracted from liver biopsy tissue, and covalently closed circular DNA was detected to predict the therapeutic value in patients. Results: At the initial stage of treatment, the level of HBV-pgRNA in phase I, II, III, and IV showed a gradual decrease. Comparing the levels of HBV-pgRNA before and after treatment, we found that the level of HBV-pgRNA was significantly lower after treatment (P < 0.05). Among the indicators for predicting HBsAg seroconversion, the accuracy of HBV-pgRNA level was 85.0% (51/60). Conclusion: The clinical value of HBV-pgRNA detection in the treatment of hepatitis B is high.

show abstract

“…Up to now, CHI3L1 is known to be stimulated by mediators such as interleukin (IL) -13, IL-6, IL-1β, and IFN-γ [6]. It is also a broblast growth factor that is highly enriched in liver and signi cantly correlated with the degree of liver brosis [7]. Intriguingly, previous studies have revealed that CHI3L1 could regulate various biological and cellular processes, including angiogenesis, in ammation, tissue remodeling, and is involved in the development of cancers [8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Serum CHI3L1 levels predict overall survival of hepatocellular carcinoma patients after hepatectomy

Jiang,

Gong,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective The Chitinase 3-like protein 1 (CHI3L1) is currently used as a biomarker for the diagnosis of liver fibrosis. However, its prognostic value for hepatocellular carcinoma (HCC) patients remains controversial. In this study, we aimed to investigate the prognostic value of the CHI3L1 in HCC patients after hepatectomy. Methods In total, 754 HCC patients who underwent curative hepatectomy between January 2017 to August 2021 were retrospectively recruited. The probability of overall survival (OS) was evaluated by the Kaplan-Meier method and compared between groups using the log-rank test. Cox proportional hazard regression analysis was used to determine the independent prognostic factors. A prognostic nomogram was constructed for further examine the clinical utility of CHI3L1 in HCC. Results Kaplan-Meier analysis revealed that elevated serum CHI3L1 levels were associated with worse overall survival of HCC patients. Multivariate Cox regression analysis showed that the high-CHI3L1 group (≥198.94 ng/ml) was associated with a shorter survival time compared with that in the low-CHI3L1 group (< 198.94 ng/ml) after adjustment for potential confounding factors (HR =1.43, 95% CI = 1.05-1.94, P = 0.024). Additionally, the nomogram had sufficient calibration and discriminatory power in the training cohort, with C-indexes of 0.723 (95% CI: 0.673-0.772). The validation cohort showed similar results. Finally, we demonstrated that the AUC of the nomogram was 0.752 (95% CI: 0.683-0.821), which had better predictive ability than AFP (AUC: 0.644, 95% CI: 0.577-0.711). Conclusion Our results confirmed that the CHI3L1 could serve as an independent predictor for OS in HCC patients after hepatectomy, thus helping clinicians to develop individualized treatment and follow-up plans for the HCC patients. Further confirmation is needed due to the study limitations.

show abstract

Relationship between liver pathologic histology and levels of serum hepatitis B virus DNA in patients with HBeAg-positive and -negative chronic hepatitis B

Cited by 3 publications

References 0 publications

Predictive Value of Serum pgRNA on HBeAg Clearance in Patients with Chronic Hepatitis B with Low HBeAg Levels Treated with Pegylated Interferon

Predictive Value of Serum pgRNA on HBeAg Clearance in Patients with Chronic Hepatitis B with Low HBeAg Levels Treated with Pegylated Interferon

Clinical Value of Hepatitis B Virus RNA Detection in Patients with Chronic Hepatitis B Infection

Serum CHI3L1 levels predict overall survival of hepatocellular carcinoma patients after hepatectomy

Contact Info

Product

Resources

About